| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | Car |
| Uniprot No | P35243 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-200aa |
| 氨基酸序列 | GNSKSGALSKEILEELQLNTKFSEEELCSWYQSFLKDCPTGRITQQQFQSIYAKFFPDTDPKAYAQHVFRSFDSNLDGTLDFKEYVIALHMTTAGKTNQKLEWAFSLYDVDGNGTISKNEVLEIVMAIFKMITPEDVKLLPDDENTPEKRAEKIWKYFGKNDDDKLTEKEFIEGTLANKEILRLIQFEPQKVKEKMKNA |
| 预测分子量 | 25.0 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CAR(嵌合抗原受体)重组蛋白的3篇示例参考文献，内容基于学术领域常见研究方向整理，供参考：
---
1. **文献名称**：*Design of Chimeric Antigen Receptors for Adoptive T Cell Therapy of Cancer*
**作者**：Sadelain, M., et al.
**摘要**：该文献综述了CAR的结构设计原理，重点探讨单链抗体片段(scFv)与共刺激信号域(如CD28、4-1BB)的优化组合，以增强T细胞抗肿瘤活性及持久性。
2. **文献名称**：*Overcoming the Solid Tumor Microenvironment with CAR-T Cell Therapy*
**作者**：Guedan, S., et al. (2018)
**摘要**：研究分析了CAR-T细胞在实体瘤治疗中的挑战，提出通过重组CAR蛋白设计(如整合趋化因子受体或免疫调节元件)改善T细胞对肿瘤微环境的穿透能力。
3. **文献名称**：*A Switch-Controlled CAR for Precise Regulation of T Cell Activity*
**作者**：Wu, C.Y., et al. (2020)
**摘要**：开发了一种可调控的CAR重组蛋白，通过外部小分子药物控制CAR的激活状态，从而减少脱靶毒性并提高治疗安全性。
---
**注意**：以上为模拟示例，实际文献需通过PubMed、Google Scholar等平台检索确认。建议使用关键词“CAR recombinant protein”、“CAR-T design”或“chimeric antigen receptor engineering”查找最新研究。
**Background of CAR Recombinant Proteins**
Chimeric antigen receptor (CAR) recombinant proteins are engineered molecules central to CAR-T cell therapy, a groundbreaking approach in immunotherapy. CARs are synthetic receptors designed to redirect immune cells, primarily T cells, to recognize and eliminate specific cancer cells. The concept emerged in the late 1980s, combining principles from immunology, genetic engineering, and oncology to enhance the precision of immune responses against tumors.
Structurally, a CAR protein typically includes three key domains: an extracellular antigen-binding domain (often derived from single-chain variable fragments of antibodies), a transmembrane domain for stability, and an intracellular signaling domain that activates T cells upon antigen recognition. Early "first-generation" CARs lacked co-stimulatory signals, limiting their persistence and efficacy. Advances led to "second-" and "third-generation" CARs incorporating domains like CD28 or 4-1BB (enhancing T cell activation) and additional signaling molecules to improve durability and anti-tumor activity.
CAR recombinant proteins are produced using recombinant DNA technology, where genes encoding these domains are cloned into viral or non-viral vectors for delivery into T cells. This process reprograms the cells to target tumor-specific antigens, such as CD19 in B-cell malignancies. CAR-T therapies have achieved remarkable success in treating refractory blood cancers, with FDA-approved products like Kymriah and Yescarta.
Challenges remain, including managing toxicities (e.g., cytokine release syndrome), improving efficacy in solid tumors (limited by antigen heterogeneity and immunosuppressive microenvironments), and reducing manufacturing complexity. Ongoing research explores "next-gen" CAR designs, such as logic-gated CARs, universal CAR-T cells, and combinations with checkpoint inhibitors. These innovations aim to expand CAR-based therapies beyond oncology into infectious diseases and autoimmunity, underscoring their transformative potential in precision medicine.
×
